WHO WE ARE

We are a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics that address significant unmet medical needs in ophthalmology, liver disease, and diabetes. Our lead candidate, Tinlarebant (LBS-008), specifically targets two retinal degenerative eye diseases: autosomal recessive Stargardt disease, type 1 (吉祥坊体育), and geographic atrophy (GA), an advanced form of age-related macular degeneration (AMD). We are traded on the Nasdaq stock exchange under the ticker BLTE.

OUR SCIENCE

People living with 吉祥坊体育 and GA share a similar pathophysiology. Their bodies produce too much retinol, which in turn produces excess toxins that accumulate in the eye causing retinal cell death and eventually loss of vision.

Retinol is produced in the liver, and retinol binding protein 4 (RBP4) carries retinol through the bloodstream from the liver to the eyes. Tinlarebant, developed from our RBP4 intellectual property portfolio, is a novel, once-a-day oral therapy aimed at reducing and then maintaining the lower level of RBP4 in the patient. In doing that, less retinol is delivered to the eye. Ultimately, by modulating the amount of retinol entering the eye, Tinlarebant could reduce the formation of vision-damaging toxins. In clinical trials, Tinlarebant has demonstrated target specificity and potency that we believe could be clinically meaningful to treat people living with 吉祥坊体育 and GA.

OUR RESEARCH

Belite research graph
We currently have several clinical trials underway with Tinlarebant, under which we will review efficacy of slowing lesion growth rate as the primary endpoint and safety and tolerability as the secondary endpoints. Tinlarebant has been granted Orphan Drug Designation in the U.S., Europe, and Japan as well as Rare Pediatric Disease (RPD) designation and Fast Track Designation (FTD) in the U.S and Sakigake (Pioneer Drug) Designation in Japan.

For the most recent news on our clinical trial progress, visit our Press Release section.

OUR TEAM

Our leadership team is comprised of individuals with significant expertise in ophthalmology drug discovery and development.

read more